Lexaria Bioscience (LEXX) EBIT (QoQ) (2017 - 2026)
Lexaria Bioscience (LEXX) EBIT (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Lexaria Bioscience | 10.36 Mn | 6.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -37.32% |
| Feb 28, 2026 | 7.74% |
| Nov 30, 2025 | 41.47% |
| Aug 31, 2025 | 28.31% |
| May 31, 2025 | -36.33% |
| Feb 28, 2025 | -2.24% |
| Nov 30, 2024 | -22.13% |
| Aug 31, 2024 | -26.40% |
| May 31, 2024 | -160.91% |
| Feb 29, 2024 | 41.36% |
| Nov 30, 2023 | -2.25% |
| Aug 31, 2023 | 53.60% |
| May 31, 2023 | -81.39% |
| Feb 28, 2023 | 21.93% |
| Nov 30, 2022 | -126.49% |
| Aug 31, 2022 | 69.05% |
| May 31, 2022 | -66.93% |
| Feb 28, 2022 | 27.69% |
| Nov 30, 2021 | -53.80% |
| Aug 31, 2021 | 49.24% |